繁體
  • 简体中文
  • 繁體中文

熱門資訊> 正文

这位全球分析师不再看涨;以下是周二的5大下调评级

2024-08-20 21:45

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

  • UBS analyst Leonardo Olmos downgraded the rating for Globant S.A. (NYSE:GLOB) from Buy to Neutral, while raised the price target from $225 to $235. Globant shares fell 1.1% to close at $201.98 on Monday. See how other analysts view this stock.
  • Citigroup analyst Thomas Singlehurst downgraded Stride, Inc. (NYSE:LRN) from Buy to Neutral, but increased the price target from $77 to $90. Stride shares gained 1.5% to close at $83.77 on Monday. See how other analysts view this stock.
  • JP Morgan analyst Tien-Tsin Huang downgraded the rating for AvidXchange Holdings, Inc. (NASDAQ:AVDX) from Overweight to Neutral and lowered the price target from $11 to $9. AvidXchange shares gained 1.4% to close at $8.24 on Monday. See how other analysts view this stock.
  • JMP Securities analyst Nicholas Jones downgraded PropertyGuru Group Limited (NYSE:PGRU) from Market Outperform to Market Perform. PropertyGuru shares settled at $6.55 on Monday. See how other analysts view this stock.
  • Benchmark analyst Robert Wasserman downgraded the rating for AbCellera Biologics Inc. (NASDAQ:ABCL) from Buy to Hold. AbCellera Biologics shares gained 3.8% to close at $2.71 on Monday. See how other analysts view this stock. See how other analysts view this stock.

Considering buying GLOB stock? Here’s what analysts think:

Read Next:

  • S&P 500, Nasdaq Extend Gains For 8th Consecutive Session: Investor Sentiment Improves, But Greed Index Remains In ‘Fear’ Zone

風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。